Literature DB >> 29946215

Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.

Koichi Kaneko1.   

Abstract

Schizophrenia is a chronic, disabling disorder, which commonly emerges in adolescence and young adulthood. While pharmacological treatment with currently available second-generation antipsychotics exerts beneficial effects on the positive symptoms of schizophrenia, they have little effect on negative symptoms or cognitive deficits. Because these two types of symptoms are enduring, and negatively impact social functioning throughout the course of the illness, there is an urgent requirement to develop new effective therapeutic approaches to manage them. Negative symptoms have proven difficult to assess accurately because of their complexity, even with commonly used clinical rating scales such as the Scales for Assessment of Negative Symptoms (SANS). In this context, new "next-generation" assessment tools have recently been developed, which include items representing the five domains encompassed by the two established clusters of negative symptoms (diminished expression and avolition), and enable the detection of changes in severity. Despite various therapeutic approaches to alleviating negative symptoms, there are currently no established methods available for clinical practice. Cognitive deficits are also a core feature in the majority of people with schizophrenia, with impaired performance observed across many cognitive domains, including verbal memory, working memory, attention, and executive functions. Such cognitive deficits are likely associated with either reduced or inefficient function of related distributed neural networks. Psychosocial treatments for cognitive impairments in schizophrenia seem promising given the beneficial effects of cognitive remediation therapy on such impairments, as well as on social functioning, as substantiated in several meta-analytic studies with modest effect sizes. Furthermore, using functional neuroimaging techniques, the size of these therapy-induced beneficial changes in neurocognitive performance has been demonstrated to be correlated with the degree of the changes in brain activation during performing some cognitive tasks in the prefrontal and temporal cortices. This suggests neurobiological effects are exerted by psychosocial cognitive remediation treatments.

Entities:  

Keywords:  cognitive impairment; cognitive remediation; motivation; negative symptoms; schizophrenia

Year:  2018        PMID: 29946215      PMCID: PMC6015796     

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  72 in total

Review 1.  A new perspective on anhedonia in schizophrenia.

Authors:  Gregory P Strauss; James M Gold
Journal:  Am J Psychiatry       Date:  2012-04       Impact factor: 18.112

Review 2.  The structure of negative symptoms within schizophrenia: implications for assessment.

Authors:  Jack J Blanchard; Alex S Cohen
Journal:  Schizophr Bull       Date:  2005-10-27       Impact factor: 9.306

Review 3.  Cognitive behavior therapy for schizophrenia.

Authors:  Douglas Turkington; David Kingdon; Peter J Weiden
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

4.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

5.  From perception to functional outcome in schizophrenia: modeling the role of ability and motivation.

Authors:  Michael F Green; Gerhard Hellemann; William P Horan; Junghee Lee; Jonathan K Wynn
Journal:  Arch Gen Psychiatry       Date:  2012-12

Review 6.  Working memory dysfunction in schizophrenia.

Authors:  P S Goldman-Rakic
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1994       Impact factor: 2.198

7.  Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.

Authors:  Paul M Grant; Gloria A Huh; Dimitri Perivoliotis; Neal M Stolar; Aaron T Beck
Journal:  Arch Gen Psychiatry       Date:  2011-10-03

Review 8.  Should schizophrenia be treated as a neurocognitive disorder?

Authors:  M F Green; K H Nuechterlein
Journal:  Schizophr Bull       Date:  1999       Impact factor: 9.306

Review 9.  Are psychotic psychopathology and neurocognition orthogonal? A systematic review of their associations.

Authors:  Maria de Gracia Dominguez; Wolfgang Viechtbauer; Claudia J P Simons; Jim van Os; Lydia Krabbendam
Journal:  Psychol Bull       Date:  2009-01       Impact factor: 17.737

10.  Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.

Authors:  Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

View more
  10 in total

1.  What Can We Learn from Animal Models to Study Schizophrenia?

Authors:  Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Adriano J M Chaves Filho; Gabriela Maciel Vieira; Danyelle Silva-Amaral; José Alexandre Crippa; João F C Pedrazzi; Danielle S Macêdo; Elaine Del-Bel; Felipe V Gomes
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Brain Derived Neurotrophic Factor and Cognitive Dysfunction in the Schizophrenia-Bipolar Spectrum: A Systematic Review and Meta-Analysis.

Authors:  Zsófia B Dombi; István Szendi; Philip W J Burnet
Journal:  Front Psychiatry       Date:  2022-05-24       Impact factor: 5.435

3.  The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial.

Authors:  Hamidreza Jamilian; Amir Ghaderi
Journal:  Biol Trace Elem Res       Date:  2021-01-06       Impact factor: 3.738

4.  Patterns of prescription of antipsychotics in Qatar.

Authors:  Sami Ouanes; Imen Becetti; Suhaila Ghuloum; Samer Hammoudeh; Mena Shehata; Hany Ghabrash; Areej Yehya; Hawra Al-Lawati; Nora Al-Fakhri; Huma Iram; Nighat Ajmal; Yassin Eltorki; Hassen Al-Amin
Journal:  PLoS One       Date:  2020-11-09       Impact factor: 3.240

5.  Loneliness, positive, negative and disorganised Schizotypy before and during the COVID-19 pandemic.

Authors:  Ronja Christensen; Corinna Haenschel; Sebastian B Gaigg; Anne-Kathrin J Fett
Journal:  Schizophr Res Cogn       Date:  2022-02-22

Review 6.  Insights into the Promising Prospect of G Protein and GPCR-Mediated Signaling in Neuropathophysiology and Its Therapeutic Regulation.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Sadia Afsana Mim; Nasrin Sultana; Dinesh Kumar Chellappan; Kamal Dua; Mohammad Amjad Kamal; Rohit Sharma; Talha Bin Emran
Journal:  Oxid Med Cell Longev       Date:  2022-09-21       Impact factor: 7.310

7.  Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study.

Authors:  Philip D Harvey; Hiroshi Nakamura; Sadanori Miura
Journal:  Neuropsychopharmacol Rep       Date:  2019-12-01

8.  Clinical determinants of social media use in individuals with schizophrenia.

Authors:  Gurpreet Rekhi; Mei San Ang; Jimmy Lee
Journal:  PLoS One       Date:  2019-11-20       Impact factor: 3.240

9.  Inability to Work Fulltime, Prevalence and Associated Factors Among Applicants for Work Disability Benefit.

Authors:  Henk-Jan Boersema; Tialda Hoekstra; Femke Abma; Sandra Brouwer
Journal:  J Occup Rehabil       Date:  2021-03-12

Review 10.  Heterogeneous trajectories in schizophrenia: insights from neurodevelopment and neuroprogression models.

Authors:  Ramiro Reckziegel; Letícia S Czepielewski; Mathias Hasse-Sousa; Dayane S Martins; Maria J de Britto; Clara de O Lapa; Alexandre W Schwartzhaupt; Clarissa S Gama
Journal:  Braz J Psychiatry       Date:  2022 Jan-Feb       Impact factor: 2.697

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.